{
    "clinical_study": {
        "@rank": "122531", 
        "arm_group": {
            "arm_group_label": "MAGE-A4 TCR Gene-Modified T Cells", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical safety and preliminary efficacy of\n      MAGE-A4 TCR Gene-Modified T lymphocytes in the treatment of malignant solid tumor patients,\n      such as malignant melanoma and lung cancer."
        }, 
        "brief_title": "Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sex: male or female\n\n          -  Age: from 18 to 80 years\n\n          -  Patients must have histologically confirmed solid tumors that have failed standard\n             therapies (surgery, chemotherapy, radiotherapy) and for which no curative options\n             exist, including, but not limited to:\n\n        Non-Small Cell Lung Carcinoma Malignant melanoma Esophageal carcinoma Head and neck\n        carcinoma\n\n          -  HLA-A*24:02\n\n          -  MAGE-A4 positive in the test by RT-PCR on tumor tissue or immunohistochemistry of\n             resected tissue of the patient.\n\n          -  PS ECOG 0 or <2\n\n          -  Laboratory tests results 7 days before the start of treatment:\n\n        White blood cells: more than 3.0 \u00d7 109/L Platelets: more than 100 \u00d7 109/L Neutrophils:\n        more than 1.5 \u00d7 109/L Hemoglobin: more than 80g/L Serum glutamate pyruvate transaminase:\n        less than 2.5 folds of the upper normal limit (ULN) Serum glutamic-oxal (o) acetic\n        transaminase: less than 2.5 \u00d7 ULN Serum bilirubin: less than 1.25 \u00d7 ULN Serum creatinine:\n        less than 1.25 \u00d7 ULN\n\n          -  Pregnancy test: the test of women of child-bearing period must be negative 7 days\n             before the start of treatment\n\n          -  Contraception: male and female subjects of child-bearing period must adopt a reliable\n             method of contraception before entry into this study until 30 days after stopping\n             this study\n\n          -  Informed consent: subject must have the ability to understand and voluntarily sign a\n             written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with life-threatening condition or complication other than their basic\n             disease\n\n          -  Pregnant or lactation. Patients both males and female with reproductive potential\n             (i.e. menopausal for less than 1 year and not surgically sterilized) must practice\n             effective contraceptive measures throughout the study. Women of childbearing\n             potential must provide a negative pregnancy test (serum or urine) within 14 days\n             prior to registration\n\n          -  Active systemic infections\n\n          -  History of neoplasms: other neoplasms\n\n          -  Medical history: active CNS disease, or congestive heart failure, or severe coronary\n             artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy\n\n          -  Metastasis: clinical symptoms of brain metastasis\n\n          -  Other clinical trial: the subject received other clinical trial before this study\n\n          -  Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B\n             virus, or hepatitis C virus was positive\n\n          -  Compliance: poor compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694472", 
            "org_study_id": "CIH-RXB-201205002"
        }, 
        "intervention": {
            "arm_group_label": "MAGE-A4 TCR Gene-Modified T Cells", 
            "description": "The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose.  The starting dose is 1-3 x 10^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10^9 cells of each TCR gene-modified cells.  Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days.  Thereafter, the patient receives peptide vaccinations on days 21 and 28.", 
            "intervention_name": "MAGE-A4 TCR Gene-Modified T Cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300060"
                }, 
                "name": "Tianjin Medical University Cancer Institute and Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Institutional Review Board of Tianjin Cancer Hospital"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CR + PR = ORR", 
            "measure": "Objective response rate", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Tianjin Medical University Cancer Institute and Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}